-
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Friday, June 1, 2018 - 1:22pm | 1014Read More...The month of May saw several drugs passing the FDA muster, with new molecular entity approvals alone totaling five. NMEs are those innovative new products containing active moieties that haven't been approved by the agency previously, either as a single ingredient drug, or as part of a...
-
Array Biopharma Sees Positive Study Results From COLUMBUS Phase 2, But Commercialization May Prove Daunting
Wednesday, May 10, 2017 - 1:12pm | 434Read More...Following Array Biopharma Inc (NASDAQ: ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink thinks it will require a sizeable commercial effort to capture share in a market that has plateaued...
-
Array Biopharma's 12% Drop, Explained
Monday, March 20, 2017 - 9:25am | 338Read More...Shares of Array Biopharma Inc (NASDAQ: ARRY), a biopharmaceutical company that focuses on drugs to treat patients suffering from cancer, lost more than 12 percent early Monday morning after announcing a disappointing update to one of its therapies. Array Biopharma announced in a press release that...
-
Why Shares Of Array Biopharma Are Surging More Than 35%
Friday, January 23, 2015 - 12:52pm | 257Read More...Shares of Array BioPharma Inc (NASDAQ: ARRY) were surging more than 30 percent on Friday after the company announced it has acquired the worldwide rights to Novartis' (NYSE: NVS) encorafenib, a BRAF inhibitor currently in a Phase-3 development for the treatment of melanoma. Array will make...
